Search Results

Your search for Annick Desjardins, MD, FRCPC,Annick Desjardins, MD, FRCPC matches 2 pages

Showing 1 - 2

By Annick Desjardins, MD, FRCPC / February 1, 2014

An Overview of the REGAL Trial and Anti-VEGF Therapies in Recurrent Glioblastoma

As published in the Journal of Clinical Oncology by Batchelor and colleagues1 and reviewed in a recent issue of The ASCO Post (November 15, 2013, page 106), the REGAL trial was a randomized, phase III, placebo-controlled, partially blinded trial evaluating the efficacy of cediranib, an...

cns cancers

By Jo Cavallo / May 25, 2015

Will the PVS-RIPO Poliovirus Be a Game Changer in the Treatment of Recurrent Glioblastoma?

Although the idea of using viruses to target cancer cells dates back more than 100 years, technologic advances in the genetic engineering of viruses are now making it possible to safely test oncolytic virotherapy as a valid strategy against cancer cells. One type of genetically engineered virus...

Dec

Today In Oncology

Search Results

Your search for Annick Desjardins, MD, FRCPC,Annick Desjardins, MD, FRCPC matches 2 pages

An Overview of the REGAL Trial and Anti-VEGF Therapies in Recurrent Glioblastoma

Will the PVS-RIPO Poliovirus Be a Game Changer in the Treatment of Recurrent Glioblastoma?

Study Finds Daratumumab Monotherapy Prevented or Delayed Progression From Smoldering to Active Multiple Myeloma

Study Finds Genetic Changes, Elevated Leukemia Risk in Ground Zero First Responders

MRI First Strategy May Be Safe for Prostate Cancer Detection

Addition of SBRT to Systemic Therapy May Improve Outcomes in Select Patients With Locally Advanced Hepatocellular Carcinoma

Epcoritamab Monotherapy for Pretreated Relapsed or Refractory CLL